纤维肌痛综合征药物治疗临床研究  

Clinical study on medication for fibromyalgia syndrome

作　　者：左文山[1] 高聿同[1] 

机构地区：[1]南京医科大学附属淮安第一医院骨二科,江苏淮安223300

出　　处：《临床骨科杂志》2005年第5期407-409,共3页Journal of Clinical Orthopaedics

摘　　要：目的探讨纤维肌痛综合征(FS)药物治疗的最佳方案、可行性依据。方法90例患者随机分为A(奥贝)、B(奥贝+阿普唑仑)、C(奥贝+奥贝汀+阿普唑仑)3组进行治疗;设对照D组(安慰剂),测定各组治疗前后的血清游离色氨酸和脑脊液中的5HT浓度。结果C组疗效明显优于A、B组;C组治疗前后游离色氨酸和5HT浓度差异有显著性,治疗前的5HT浓度与病情总积分呈负相关。结论患者脑脊液中的5HT在肌痛的发生中起关键作用,与FS的发生呈负相关。抗抑郁是治疗FS的中心环节,使用以奥贝汀为主的三联药物疗法,疗效满意。Objective To investigate the optimal medication regimen for fibromyalgia syndrome. Methods 90 cases were randomized into 3 groups： Group A （Apo-DICLO） , Group B （ Apo-DICLO and alprazolam） and Group C （Apo-fluoxetine associate with Apo-DICLO and alprazolam） , and were treated accordingly. Group D was designed as control. The densities of free serum tryptophan and CSF 5-HT were detected before and after treatment. Results The effect of Group C was better than those of A and B. In Group C, the densities of free serum tryptophan and CSF 5-HT were significant different before and after treatment. The preoperative 5-HT density was negatively related to the severity scores. Conclusions CSF 5-HT plays important role in the pathogenesis of fibromyalgia syndrome and is negatively related to the severity. Antidepressant is the main treatment of fibromyalgia syndrome, and the triple medication with Apo-fluoxetine can provide satisfaetory outcome.

关 键 词：纤维肌痛/药物疗法 非甾类消炎药 抗抑郁类药物 5-羟色胺 游离色氨酸 

分 类 号：R685[医药卫生—骨科学] R971.43[医药卫生—外科学]